Pharmaceuticals 2012, 5(11), 1160-1176; doi:10.3390/ph5111160
Review

Cyclooxygenase (COX) Inhibitors and the Newborn Kidney

1 Department of Physiology and Pharmacology, University of Calgary, Alberta, T2N 4N1, Canada 2 Alberta Children's Hospital Research Institute for Child and Maternal Health, University of Calgary, Alberta, T2N 4N1, Canada 3 Department of Pediatrics, University of Calgary, Alberta, T2N 4N1, Canada
* Author to whom correspondence should be addressed.
Received: 17 August 2012; in revised form: 28 September 2012 / Accepted: 15 October 2012 / Published: 25 October 2012
(This article belongs to the Special Issue Cyclooxygenase(COX) Inhibitors)
PDF Full-text Download PDF Full-Text [488 KB, Updated Version, uploaded 26 October 2012 14:48 CEST]
The original version is still available [368 KB, uploaded 25 October 2012 11:57 CEST]
Abstract: This review summarizes our current understanding of the role of cyclo-oxygenase inhibitors (COXI) in influencing the structural development as well as the function of the developing kidney. COXI administered either during pregnancy or after birth can influence kidney development including nephronogenesis, and can decrease renal perfusion and ultrafiltration potentially leading to acute kidney injury in the newborn period. To date, which COX isoform (COX-1 or COX-2) plays a more important role in during fetal development and influences kidney function early in life is not known, though evidence points to a predominant role for COX-2. Clinical implications of the use of COXI in pregnancy and in the newborn infant are also evaluated herein, with specific reference to the potential effects of COXI on nephronogenesis as well as newborn kidney function.
Keywords: perinatal; prostaglandins; newborn; patent ductus arteriosis; premature labour; indomethacin; COX-1; COX-2; neonate; COX inhibitors

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Smith, F.G.; Wade, A.W.; Lewis, M.L.; Qi, W. Cyclooxygenase (COX) Inhibitors and the Newborn Kidney. Pharmaceuticals 2012, 5, 1160-1176.

AMA Style

Smith FG, Wade AW, Lewis ML, Qi W. Cyclooxygenase (COX) Inhibitors and the Newborn Kidney. Pharmaceuticals. 2012; 5(11):1160-1176.

Chicago/Turabian Style

Smith, Francine G.; Wade, Andrew W.; Lewis, Megan L.; Qi, Wei. 2012. "Cyclooxygenase (COX) Inhibitors and the Newborn Kidney." Pharmaceuticals 5, no. 11: 1160-1176.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert